{"id":"https://openalex.org/W2008181555","doi":"https://doi.org/10.1073/pnas.96.4.1591","title":"Synergy between an antiangiogenic integrin \u03b1 v antagonist and an antibody\u2013cytokine fusion protein eradicates spontaneous tumor metastases","display_name":"Synergy between an antiangiogenic integrin \u03b1 v antagonist and an antibody\u2013cytokine fusion protein eradicates spontaneous tumor metastases","publication_year":1999,"publication_date":"1999-02-16","ids":{"openalex":"https://openalex.org/W2008181555","doi":"https://doi.org/10.1073/pnas.96.4.1591","mag":"2008181555","pmid":"https://pubmed.ncbi.nlm.nih.gov/9990069","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/15528"},"language":"en","primary_location":{"id":"doi:10.1073/pnas.96.4.1591","doi":"https://doi.org/10.1073/pnas.96.4.1591","is_oa":false,"landing_page_url":"https://doi.org/10.1073/pnas.96.4.1591","pdf_url":null,"source":{"id":"https://openalex.org/S125754415","display_name":"Proceedings of the National Academy of Sciences","issn_l":"0027-8424","issn":["0027-8424","1091-6490"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320052","host_organization_name":"National Academy of Sciences","host_organization_lineage":["https://openalex.org/P4310320052"],"host_organization_lineage_names":["National Academy of Sciences"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Proceedings of the National Academy of Sciences","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/15528","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018970052","display_name":"Holger N. Lode","orcid":"https://orcid.org/0000-0002-1201-208X","observed_orcids":["https://orcid.org/0000-0002-1201-208X"]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Holger N. Lode","raw_affiliation_strings":["The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173","institution_ids":["https://openalex.org/I123431417"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101975428","display_name":"Thomas M. Moehler","orcid":"https://orcid.org/0000-0003-1495-8917","observed_orcids":["https://orcid.org/0000-0003-1495-8917"]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Moehler","raw_affiliation_strings":["The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173","institution_ids":["https://openalex.org/I123431417"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021561362","display_name":"Rong Xiang","orcid":"https://orcid.org/0000-0003-3487-7348","observed_orcids":["https://orcid.org/0000-0003-3487-7348","https://orcid.org/0009-0003-2941-4397"]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rong Xiang","raw_affiliation_strings":["The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173","institution_ids":["https://openalex.org/I123431417"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109986055","display_name":"Alfred Jonczyk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alfred Jonczyk","raw_affiliation_strings":["The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173","institution_ids":["https://openalex.org/I123431417"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000263428","display_name":"Stephen D. Gillies","orcid":"https://orcid.org/0000-0002-2080-4220","observed_orcids":["https://orcid.org/0000-0002-2080-4220"]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen D. Gillies","raw_affiliation_strings":["The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173","institution_ids":["https://openalex.org/I123431417"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089796560","display_name":"David A. Cheresh","orcid":"https://orcid.org/0000-0002-7193-8595","observed_orcids":["https://orcid.org/0000-0002-7193-8595"]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David A. Cheresh","raw_affiliation_strings":["The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173","institution_ids":["https://openalex.org/I123431417"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103782744","display_name":"Ralph A. Reisfeld","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ralph A. Reisfeld","raw_affiliation_strings":["The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037; Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany; and Lexigen Pharmaceuticals Corp., 125 Hartwell Avenue, Lexington, MA 02173","institution_ids":["https://openalex.org/I123431417"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I123431417"],"apc_list":null,"apc_paid":null,"fwci":4.4512,"has_fulltext":false,"cited_by_count":127,"citation_normalized_percentile":{"value":0.95517488,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"96","issue":"4","first_page":"1591","last_page":"1596"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10831","display_name":"Cell Adhesion Molecules Research","score":0.008700000122189522,"subfield":{"id":"https://openalex.org/subfields/2723","display_name":"Immunology and Allergy"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0024999999441206455,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.8840000033378601},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5040000081062317},{"id":"https://openalex.org/keywords/metastasis","display_name":"metastasis","score":0.7059999704360962},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":0.9509999752044678},{"id":"https://openalex.org/keywords/neuroblastoma","display_name":"neuroblastoma","score":0.9890000224113464},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9539999961853027},{"id":"https://openalex.org/keywords/colon-cancer","display_name":"colon cancer","score":0.9919999837875366},{"id":"https://openalex.org/keywords/tumor-vasculature","display_name":"tumor vasculature","score":0.8930000066757202},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.9079999923706055},{"id":"https://openalex.org/keywords/tumor-necrosis","display_name":"tumor necrosis","score":0.8009999990463257},{"id":"https://openalex.org/keywords/tumor-microvessel-density","display_name":"tumor microvessel density","score":0.6320000290870667},{"id":"https://openalex.org/keywords/inflammatory-cells","display_name":"inflammatory cells","score":0.5059999823570251}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6278623342514038},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6066509485244751},{"id":"https://openalex.org/C123894998","wikidata":"https://www.wikidata.org/wiki/Q425158","display_name":"Fusion protein","level":4,"score":0.5786958336830139},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.5647523999214172},{"id":"https://openalex.org/C2776715637","wikidata":"https://www.wikidata.org/wiki/Q938205","display_name":"Neuroblastoma","level":3,"score":0.5639040470123291},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5503985285758972},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.5203108787536621},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5068874955177307},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.4970536530017853},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.4905966818332672},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.48609352111816406},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.48099029064178467},{"id":"https://openalex.org/C195687474","wikidata":"https://www.wikidata.org/wiki/Q409715","display_name":"Integrin","level":3,"score":0.4722708463668823},{"id":"https://openalex.org/C2780283643","wikidata":"https://www.wikidata.org/wiki/Q2110267","display_name":"Primary tumor","level":4,"score":0.45076900720596313},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.446329265832901},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4261644184589386},{"id":"https://openalex.org/C2779256057","wikidata":"https://www.wikidata.org/wiki/Q16909647","display_name":"Tumor progression","level":3,"score":0.4125405550003052},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.38833868503570557},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3554086685180664},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3409194350242615},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.23065635561943054},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.195613294839859},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.19184640049934387},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.13787546753883362},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.10626885294914246},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.0586218535900116},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000922","descriptor_name":"Immunotoxins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003110","descriptor_name":"Colonic Neoplasms","qualifier_ui":"Q000098","qualifier_name":"blood supply","is_major_topic":false},{"descriptor_ui":"D003110","descriptor_name":"Colonic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D003110","descriptor_name":"Colonic Neoplasms","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007376","descriptor_name":"Interleukin-2","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008546","descriptor_name":"Melanoma, Experimental","qualifier_ui":"Q000098","qualifier_name":"blood supply","is_major_topic":false},{"descriptor_ui":"D008546","descriptor_name":"Melanoma, Experimental","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008546","descriptor_name":"Melanoma, Experimental","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D009389","descriptor_name":"Neovascularization, Pathologic","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D009447","descriptor_name":"Neuroblastoma","qualifier_ui":"Q000098","qualifier_name":"blood supply","is_major_topic":false},{"descriptor_ui":"D009447","descriptor_name":"Neuroblastoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009447","descriptor_name":"Neuroblastoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D010456","descriptor_name":"Peptides, Cyclic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012910","descriptor_name":"Snake Venoms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014407","descriptor_name":"Tumor Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015703","descriptor_name":"Antigens, CD","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D019030","descriptor_name":"Receptors, Vitronectin","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D019030","descriptor_name":"Receptors, Vitronectin","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D039564","descriptor_name":"Integrin alphaV","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1073/pnas.96.4.1591","doi":"https://doi.org/10.1073/pnas.96.4.1591","is_oa":false,"landing_page_url":"https://doi.org/10.1073/pnas.96.4.1591","pdf_url":null,"source":{"id":"https://openalex.org/S125754415","display_name":"Proceedings of the National Academy of Sciences","issn_l":"0027-8424","issn":["0027-8424","1091-6490"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320052","host_organization_name":"National Academy of Sciences","host_organization_lineage":["https://openalex.org/P4310320052"],"host_organization_lineage_names":["National Academy of Sciences"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Proceedings of the National Academy of Sciences","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:1234510","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/15528","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:15528","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/15528","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Proc Natl Acad Sci U S A","raw_type":"Text"},{"id":"pmid:9990069","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9990069","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Proceedings of the National Academy of Sciences of the United States of America","raw_type":"Journal Article"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:1234510","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/15528","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1602455367","display_name":null,"funder_award_id":"CA-42508","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G1648785187","display_name":null,"funder_award_id":"CA-50286","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G2003983467","display_name":null,"funder_award_id":"CA-45726","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G243309107","display_name":"Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors","funder_award_id":"R01CA045726","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G4572209492","display_name":"CRAF-mediated vascular resistance to cancer therapies","funder_award_id":"R01CA050286","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G6076592392","display_name":"MOLECULAR PROFILE OF MELANOMA AND NEUROBLASTOMA ANTIGENS","funder_award_id":"R35CA042508","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G6100102529","display_name":"VEGF and PDGF in angiogenesis and tumor progression","funder_award_id":"R37CA050286","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W272579771","https://openalex.org/W1554296669","https://openalex.org/W1570734769","https://openalex.org/W1579297325","https://openalex.org/W1794218190","https://openalex.org/W1965605868","https://openalex.org/W1989115595","https://openalex.org/W2000000541","https://openalex.org/W2001753204","https://openalex.org/W2009240587","https://openalex.org/W2025329768","https://openalex.org/W2029773366","https://openalex.org/W2039317622","https://openalex.org/W2072313116","https://openalex.org/W2072928113","https://openalex.org/W2088272913","https://openalex.org/W2113267611","https://openalex.org/W2118326757","https://openalex.org/W2122042627","https://openalex.org/W2138985980","https://openalex.org/W2155392902"],"related_works":["https://openalex.org/W1997201694","https://openalex.org/W2319871595","https://openalex.org/W2164006518","https://openalex.org/W2625888858","https://openalex.org/W1764828245","https://openalex.org/W2064342667","https://openalex.org/W1963810538","https://openalex.org/W2069937695","https://openalex.org/W7100736177","https://openalex.org/W2171438857"],"abstract_inverted_index":{"The":[0,205],"suppression":[1],"and":[2,7,25,40,51,59,116,136,173,217],"eradication":[3],"of":[4,14,23,62,76,223],"primary":[5,123],"tumors":[6],"distant":[8],"metastases":[9,69],"is":[10],"a":[11,31,44,71,146,165,174,215],"major":[12],"goal":[13],"alternative":[15],"treatment":[16,211],"strategies":[17],"for":[18,153,220],"cancer,":[19],"such":[20],"as":[21,142,203],"inhibition":[22],"angiogenesis":[24],"targeted":[26],"immunotherapy.":[27],"We":[28],"report":[29],"here":[30],"synergy":[32],"between":[33],"two":[34],"novel":[35,216],"monotherapies":[36,64,86],"directed":[37],"against":[38],"vascular":[39],"tumor":[41,45,124,130,149,170,182,185],"compartments,":[42],"respectively,":[43],"vasculature-specific":[46],"antiangiogenic":[47,90],"integrin":[48,91,113],"alphav":[49,92,114],"antagonist":[50,93,115],"tumor-specific":[52,117],"antibody-interleukin":[53],"2":[54],"(IL-2)":[55],"fusion":[56,96,119],"proteins.":[57],"Simultaneous":[58],"sequential":[60],"combination":[61,194],"these":[63,209],"effectively":[65],"eradicated":[66],"spontaneous":[67],"liver":[68],"in":[70,80,126,148,169,177,180,190],"poorly":[72],"immunogenic":[73],"syngeneic":[74,128],"model":[75],"neuroblastoma.":[77,137],"This":[78],"was":[79,156,162,187,201],"contrast":[81],"to":[82,85],"controls":[83],"subjected":[84],"with":[87,111],"either":[88],"an":[89],"or":[94],"antibody-IL-2":[95,118],"proteins,":[97],"which":[98],"were":[99],"only":[100,145,189],"partially":[101],"effective":[102,218],"at":[103],"the":[104,112,159,181,193],"dose":[105],"levels":[106],"applied.":[107],"Furthermore,":[108],"simultaneous":[109,166],"treatments":[110],"proteins":[120],"induced":[121,144],"dramatic":[122],"regressions":[125],"three":[127],"murine":[129],"models,":[131],"i.e.,":[132],"melanoma,":[133],"colon":[134],"carcinoma,":[135],"However,":[138],"each":[139,199],"agent":[140,200],"used":[141],"monotherapy":[143],"delay":[147],"growth.":[150],"A":[151],"mechanism":[152],"this":[154],"synergism":[155],"suggested":[157],"because":[158],"antitumor":[160],"response":[161],"accompanied":[163],"by":[164],"50%":[167],"reduction":[168],"vessel":[171],"density":[172],"5-fold":[175],"increase":[176],"inflammatory":[178],"cells":[179],"microenvironment.":[183],"Subsequently,":[184],"necrosis":[186],"demonstrated":[188],"animals":[191],"receiving":[192],"therapy,":[195],"but":[196],"not":[197],"when":[198],"applied":[202],"monotherapy.":[204],"results":[206],"suggest":[207],"that":[208],"synergistic":[210],"modalities":[212],"may":[213],"provide":[214],"tool":[219],"future":[221],"therapies":[222],"metastatic":[224],"cancer.":[225]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}